Throughout the redesign process for the new babyLance that it launched last month, MediPurpose actively involved end-users to learn more about their requirements and to validate that its new infant heel incision device was meeting their expectations.
According to the white paper, in early 2012, MediPurpose conducted a series of simulated use studies (SUS) to validate its latest babyLance design. In those studies, 33 neonatal nurses at five hospitals in California and Georgia were given pre-production babyLance devices to use on a replica infant heel so they could complete an evaluation survey and report their experiences to MediPurpose.
The SUS results indicated that the new babyLance design consistently met or exceeded end-users' expectations and requirements. Evaluation scores for safety, training, ergonomics, trigger activation and usage also exceeded MediPurpose's minimums, enabling the company to proceed with the babyLance development project.
The white paper is the latest in a series of publications that illustrate MediPurpose's intensive research and testing for its new neonatal heel incision device, including white papers on heelstick cut profiles for babyLance and leading competitors, a heelstick trigger activation survey at the 2011 NANN convention, and an overview of its research on neonatal heelstick user preferences.
"MediPurpose certainly did not invent the infant heelstick-a medical device that has been around for several years," said MediPurpose founder and CEO Patrick Yi, who led the babyLance design team. "However, the market has expressed the need for a neonatal heelstick that better satisfies its end-users' unique requirements. By listening to the end-users, we are confident that our new babyLance meets their requirements."
Yi said that his company's confidence is fostered by the knowledge that its new babyLance:
* Is designed with intensive input from a diverse range of highly qualified users.
* Provides a preferred pull trigger activation mechanism that is comfortable and easy to use.
* Is assured to provide safety and quality from a proven and trusted manufacturer with worldwide distribution channels.
Additionally, Yi said that ╥the results further validate MediPurpose's medical product innovation process and capabilities."
About babyLance Infant Heel Incision Devices
The new babyLance infant heel incision device is a fully redesigned iteration of MediPurpose's original safe, easy and effective heelstick device.
Used by neonatal caregivers to collect blood samples from infants, the new babyLance features an ergonomic design to provide a secure and stable grip.
Combined with a redesigned trigger mechanism, the heelstick device is easy to activate, helping to deliver a consistent incision without damaging the baby's tender nerve fibers.
babyLance heelstick devices are available in two models:
* The babyLance BLP (Preemie), which delivers an incision depth of 0.85 mm.
* The babyLance BLN (Newborn), which delivers an incision depth of 1.00 mm.
To download the white papers, please visit http://www.medipurpose.com/
For more information about babyLance -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm)
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.